Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Phase I Trial of Venetoclax and BEAM Followed by Autologous Stem Cell Transplant for High-Risk Non-Hodgkin Lymphoma.

Transplantation and cellular therapy·2026

Same author

A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.

Blood advances·2026

Same author

Risk Factors for Solid Organ Graft Failure and Death in Solid Organ Transplant Recipients Undergoing Hematopoietic Cell Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research (CIBMTR) and Organ Procurement and Transplantation Network (OPTN) Study.

Transplantation·2025

Same author

Risk Factors for Solid Organ Graft Failure and Death in Hematopoietic Cell Transplant Recipients Undergoing Solid Organ Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research and Organ Procurement and Transplantation Network Study.

Transplantation·2025

Same author

Narrowing of the Racial Disparities Gap in Survival of Patients With Mycosis Fungoides: A Longitudinal Analysis of the SEER Database.

Clinical lymphoma, myeloma & leukemia·2025

Same author

Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies.

Cytometry. Part B, Clinical cytometry·2024

Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026

Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026

Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026

Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026

Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026

Same journal

Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering-an expert perspective.

Expert opinion on biological therapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 11, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [¹⁸F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

I-131 tositumomab.

Basem M William¹, Philip J Bierman

¹Oncology/Hematology, University of Nebraska Medical Center, Omaha, NE 68198-7680. USA. bwillia@unmc.edu

Expert Opinion on Biological Therapy

|July 2, 2010

Summary

This summary is machine-generated.

I-131 tositumomab offers a safe and effective treatment for recurrent or refractory follicular lymphoma (FL). This radioimmunoconjugate also shows promise for upfront FL treatment and aggressive B-cell lymphomas.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Synthesis of 68Ga Core-doped Iron Oxide Nanoparticles for Dual Positron Emission Tomography /(T1)Magnetic Resonance Imaging

Synthesis of ⁶⁸Ga Core-doped Iron Oxide Nanoparticles for Dual Positron Emission Tomography /(T₁)Magnetic Resonance Imaging

Published on: November 20, 2018

Related Experiment Videos

Last Updated: Jun 11, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [¹⁸F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Synthesis of 68Ga Core-doped Iron Oxide Nanoparticles for Dual Positron Emission Tomography /(T1)Magnetic Resonance Imaging

Synthesis of ⁶⁸Ga Core-doped Iron Oxide Nanoparticles for Dual Positron Emission Tomography /(T₁)Magnetic Resonance Imaging

Published on: November 20, 2018

Area of Science:

Oncology
Hematology
Radiopharmaceutical Therapy

Background:

Follicular lymphoma (FL) constitutes 15-30% of all non-Hodgkin's lymphomas (NHL).
I-131 tositumomab is a radioimmunoconjugate targeting CD20, approved for recurrent, refractory, or transformed FL.

Purpose of the Study:

To review the clinical pharmacology, efficacy, and safety of I-131 tositumomab.
To evaluate its use in various B-NHL settings and transplant conditioning.

Main Methods:

Review of clinical pharmacology and dosing of I-131 tositumomab.
Analysis of key clinical trials for efficacy and safety data.
Assessment of safety and regulatory aspects.

Main Results:

I-131 tositumomab is effective as a second-line treatment for FL.
Data supports its use in the upfront treatment of FL and aggressive B-NHL.

Conclusions:

I-131 tositumomab is a safe and effective option for recurrent, refractory, or transformed FL.
It holds promise for upfront FL treatment, aggressive B-NHL, and as a transplant conditioning regimen.